Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Barry

Showing results (541-550 of 674) with videos related to

Pageof 68
Sort By:
NPJ Breast Cancer|August 8, 2018
Unraveling the clinicopathological features driving the emergence of <i>ESR1</i> mutations in metastatic breast cancerYanan Kuang, Bilal Siddiqui, Jiani Hu, et al.
Science Signaling|February 27, 2024
Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradationEmily C Erickson, Inchul You, Grace Perry, et al.
The AAPS Journal|June 17, 2017
Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance)Shailly Mehrotra, Manish R Sharma, Elizabeth Gray, et al.
Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology|March 21, 2022
Systemic Bioavailability of Sublingual Atropine Ophthalmic Solution: a Phase I Study in Healthy Volunteers with Implications for Use as a Contingency Medical CountermeasureMichael D Schwartz, Robert Raulli, Judith W Laney, et al.
International Journal of Cancer|October 27, 2009
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivoMichael A Morse, Junping Wei, Zachary Hartman, et al.
Drug Discovery Today|June 4, 2013
Model-based drug discovery: implementation and impactSandra A G Visser, Malin Aurell, Rhys D O Jones, et al.
Disease Models & Mechanisms|February 28, 2025
Use of metabolic imaging to monitor heterogeneity of tumour response following therapeutic mTORC1/2 pathway inhibitionStephanie Ling, Alex Dexter, Alan M Race, et al.
Cell Metabolism|December 3, 2015
Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal CancerAurélien J C Pommier, Matthew Farren, Bhavika Patel, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2026
Coexistent <i>PTEN</i> and <i>PIK3CA</i> alterations hyperactivate mTORC1 signaling in endometrial cancers and cause their selective sensitivity to mTORC1 inhibitionHilla Solomon, Radha Mukherjee, Yu Chi Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2017
Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null TumorsJames T Lynch, Urszula M Polanska, Oona Delpuech, et al.
Pageof 68

Showing results (541-550 of 674) with videos related to

Sort By:
Pageof 68
NPJ Breast Cancer|August 8, 2018
Unraveling the clinicopathological features driving the emergence of <i>ESR1</i> mutations in metastatic breast cancerYanan Kuang, Bilal Siddiqui, Jiani Hu, et al.
Science Signaling|February 27, 2024
Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradationEmily C Erickson, Inchul You, Grace Perry, et al.
The AAPS Journal|June 17, 2017
Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance)Shailly Mehrotra, Manish R Sharma, Elizabeth Gray, et al.
Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology|March 21, 2022
Systemic Bioavailability of Sublingual Atropine Ophthalmic Solution: a Phase I Study in Healthy Volunteers with Implications for Use as a Contingency Medical CountermeasureMichael D Schwartz, Robert Raulli, Judith W Laney, et al.
International Journal of Cancer|October 27, 2009
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivoMichael A Morse, Junping Wei, Zachary Hartman, et al.
Drug Discovery Today|June 4, 2013
Model-based drug discovery: implementation and impactSandra A G Visser, Malin Aurell, Rhys D O Jones, et al.
Disease Models & Mechanisms|February 28, 2025
Use of metabolic imaging to monitor heterogeneity of tumour response following therapeutic mTORC1/2 pathway inhibitionStephanie Ling, Alex Dexter, Alan M Race, et al.
Cell Metabolism|December 3, 2015
Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal CancerAurélien J C Pommier, Matthew Farren, Bhavika Patel, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2026
Coexistent <i>PTEN</i> and <i>PIK3CA</i> alterations hyperactivate mTORC1 signaling in endometrial cancers and cause their selective sensitivity to mTORC1 inhibitionHilla Solomon, Radha Mukherjee, Yu Chi Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2017
Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null TumorsJames T Lynch, Urszula M Polanska, Oona Delpuech, et al.
Pageof 68